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Section A 
Multiple Choice Questions 
Total No of Marks for this section: 45 
 
This section should be answered on the Answer Sheet provided.  Please ensure that your name 
and student number have been written on the Answer sheet and place in the completed 
answer Booklet. 
Marks for each question are indicated.  Suggested Time allocation for Section A: 50 mins 
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Section B 
Short Answer Questions 
Total No of Marks for this section: 66 
 
This section should be answered in the Answer Booklet provided. 
 




The diagram below shows the structure of Isoprenaline (C11H18NO3), a bronchodilator and 
cardiotonic drug. It also selectively binds to and activates beta-adrenergic receptors. 
  
(a) Redraw the structure in your answer paper and label all the possible binding 
interactions that can take place in the binding site between isoprenaline molecule and 
the amino acid residues of the beta-adrenergic receptor protein involved.   
(Marks: 1) 
(b) What is meant by de novo drug design?   
(Marks: 1) 
(c) The logP value of Isoprenaline is 5.6 and its molar mass is 296.15 g/mol. Calculate the 
other properties of Isoprenaline relating to ‘Lipinski-Rule of Five’. State whether the 
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Question 2 
The logP value for benzene = 2.13 
The π values for different substituents are as follows: 
 π(OH) =  -0.67  
 π(I) = 1.12;  
 π(CONH2) = - 1.49 
 
(a) Calculate the logP value for the following compounds. Which compound would be the 
least hydrophobic? 
 i)    ii)  iii)  
 (Marks: 4) 
 
(b) The graph below represents a plot of %concentration versus pH of Meclofenamic acid. 
Meclofenamic acid has a logP value of 5.6 and its pKa value is 3.8. 
 
(c) Calculate the log D value of the molecule at pH 5.5. 
  -- for acids 
 -- for bases 
 (Marks: 2) 
(d) Discuss the nature of the major species at pH 5.5. 
 (Marks: 2) 
THIS EXAMINATION PAPER AND SUPPLIED MATERIALS ARE NOT PERMITTED TO BE REMOVED FROM 
ANY EXAMINATION VENUE IN ANY CIRCUMSTANCE. THIS EXAMINATION IS PRINTED DOUBLE-SIDED. 
 
Semester 2, 2016 FINAL EXAMINATION 
 PHA214 – Biotechnology and Pharmacogenomics  
Page 6 of 9 
Question 3 
(a) During homology modelling, state the two important criteria you would apply to choose 
a template protein. 
(Marks: 2) 
(b) State and explain one important method that you would use to validate the homology 
model of a protein.  
(Marks: 2) 
(c) Explain the significance of the  Hammet constant (σ) 
  
 (Marks: 2) 
(d) Using the data provided in the table below, explain which functional group you would 





The enzyme dihydropyrimidine dehydrogenase metabolises drugs such as 5-fluorouracil (an 
anticancer drug) to inactive metabolites. Effects associated with high doses of 5-fluorouracil 
include neurotoxicity (damage to the nerves). In a small proportion (0.1%) of the population 
the enzyme dihydropyrimidine dehydrogenase is totally inactive. In these individuals side 
effects such as neurotoxicity are observed.  
(a) What patient information should be known for someone about to start 5-fluorouracil 
treatment? Why?  
 (Marks: 4) 
(b) How could this information be determined? 
(Marks: 2) 
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Question 5 
Mary, a 28-year-old women was receiving carbamazepine (a CYP3A4 substrate), 1000 mg/day; 
blood level of 9.3 µg/mL for the treatment of bipolar disorder. During winter, she contracts 
bronchitis and she is prescribed Erythromycin for 10 day. The patient experienced increasing 
sedation and ataxis (lack of muscle coordination) over the next few days, and on the fifth day 
she experienced a fall without loss of consciousness. She was taken to emergency department 
(ED), where her carbamazepine blood levels were found to be double. She was admitted to 
hospital and her carbamazepine levels were reduced to 500 mg/day, and she was discharged 
from the hospital after 2 days. She did not encounter any further problems with the remainder 
of her erythromycin course. However, 5 days after finishing this course, she experienced her 
first and only seizure. She was discovered by her boyfriend, who called an ambulance and she 
was again taken to ED, where her carbamazepine blood levels were found to be 4.1 µg/mL.  
(a) Explain why Mary was taken to the ED the first time. 
(Marks: 3) 
 




Discuss the different components of a cytochrome P450 enzyme and the importance of each in 
relation to Phase I metabolism. 
 (Marks: 6) 
 
Question 7 
(a) Explain the mechanism of induction for cytochrome P450 1A1. 
 (Marks: 5) 
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Question 8 




The following is DNA sequence of the wild type allele of gene Z that you want to amplify using 
polymerase chain reaction (PCR).  
 5’CTCGAGGTGAATATGAAAG---   ---CATTTGGCGCGTAATCGATA3’ 
 3’GAGCTCCACTTATACTTTC---  ---GTAAACCGCGCATTAGCTAT5’ 
 
(a) If you amplify a DNA sequence through PCR what are the component that you would 
absolutely require? Briefly state the function of each. 
 (Marks: 4) 
(b) Circle the set of primers that you would use for the PCR in part (a)? 
Set 1: 5’TACACTTATACTTTC3’ & 5’GATTACGCGCCAAATG3’ 
Set 2: 5’CTCGAGGTGAATAT3’ & 5’TATCGATTACGCGCC3’ 
Set 3: 5’GAGTTACACTTATAC3’ & 5’ATAGCTAATGAGCGGT3’ 
(Marks: 1) 
(c) In PCR, you need specific conditions to ensure exponential growth of DNA molecules. 
Briefly explain what these conditions are, what is occurring and the temperatures they 
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Question 10 
You find a plasmid that you think carries gene X, but you need to confirm that the target gene 
has been inserted. When you made your construct you cut your DNA with EcoRI and cloned it 
into a EcoRI restriction site in the vector. 
(a) How could you check to see if gene X has been cloned? 
(Marks: 3) 
 
You find that gene X has been inserted into the plasmid, but now you want to 
determine the restriction map of the recombinant plasmid. You digest the plasmid with 













(b) Draw a restriction map of the recombinant plasmid that you have created. 
(Marks: 3) 
 
………………………….end of the paper………………………………. 
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